- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1032823-75-8] GSK1292263
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-12066 |
| Brand: | MCE |
| CAS: | 1032823-75-8 |
Overview
| MDL | MFCD18385004 |
|---|---|
| Molecular Weight | 456.56 |
| Molecular Formula | C23H28N4O4S |
| SMILES | CC(C1=NOC(N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(C)(=O)=O)=N1)C |
3 Publications Citing Use of MCE
Summary
In Vivo
GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male neonatal Streptozotocin (STZ)-induced SD rats (7 weeks of age) [2] |
| Dosage: | 30 mg/kg |
| Administration: | Orally given; once a day for 2 weeks |
| Result: | The AUC of plasma glucose (AUC PG ) in the single treatment of the GSK1292263 group was numerically lower than that of the vehicle group, but the effect was modest. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01128621 | GlaxoSmithKline |
Diabetes Mellitus, Type 2
|
November 23, 2009 | Phase 2 |
| NCT01218204 | GlaxoSmithKline |
Dyslipidaemias|Dyslipidemias
|
September 14, 2010 | Phase 2 |
| NCT01119846 | GlaxoSmithKline |
Diabetes Mellitus, Type 2
|
June 5, 2009 | Phase 2 |
| NCT01101568 | GlaxoSmithKline |
Diabetes Mellitus, Type 2
|
April 14, 2010 | Phase 1 |
| NCT00783549 | GlaxoSmithKline |
Dyslipidaemias
|
September 4, 2008 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 20 mg/mL ( 43.81 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1903 mL | 10.9515 mL | 21.9029 mL |
| 5 mM | 0.4381 mL | 2.1903 mL | 4.3806 mL |
| 10 mM | 0.2190 mL | 1.0951 mL | 2.1903 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2 mg/mL (4.38 mM); Clear solution
References
- [1] X. Zhu, et al. GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment.
- [2] Koji Matsumoto, et al. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. J Pharmacol Exp The
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.